Halozyme Therapeutics, Inc.HALONASDAQ
Loading
SG&A Expense Growth TrendStable
Percentile Rank71
3Y CAGR-48.5%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
-48.5%/yr
vs +94.3%/yr prior
Acceleration
-142.8pp
Decelerating
Percentile
P71
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthStable
PeriodValue
202525.31%
20243.45%
20233.94%
2022185.21%
202110.03%
2020-40.80%
201927.05%
201812.98%
201717.37%
201614.55%